Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
Hernández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, Hernández-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Díaz C, Hernández G, Egido J. Hernández-Presa MA, et al. Among authors: hernandez g, hernandez vargas p. Atherosclerosis. 2002 Jan;160(1):49-58. doi: 10.1016/s0021-9150(01)00547-0. Atherosclerosis. 2002. PMID: 11755922
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month.
Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-García B, Vega M, Serrano J, Ortega L, Hernández G, Tuñón J, Egido J. Martín-Ventura JL, et al. Among authors: hernandez g. Stroke. 2005 Aug;36(8):1796-800. doi: 10.1161/01.STR.0000174289.34110.b0. Epub 2005 Jul 14. Stroke. 2005. PMID: 16020773 Clinical Trial.
Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization.
Gómez-Hernández A, Sánchez-Galán E, Martín-Ventura JL, Vidal C, Blanco-Colio LM, Ortego M, Vega M, Serrano J, Ortega L, Hernández G, Tunón J, Egido J. Gómez-Hernández A, et al. Among authors: hernandez g. J Cardiovasc Pharmacol. 2006 Jan;47(1):60-9. doi: 10.1097/01.fjc.0000194252.38683.68. J Cardiovasc Pharmacol. 2006. PMID: 16424787
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, Civeira F, Hernández A, da Silva PM, Rodriguez-Botaro A, Zambón D, Lima J, Díaz C, Aristegui R, Sol JM, Chaves J, Hernández G; ATOMIX Investigators. Gómez-Gerique JA, et al. Among authors: hernandez g, hernandez a. Atherosclerosis. 2002 Jun;162(2):245-51. doi: 10.1016/s0021-9150(01)00708-0. Atherosclerosis. 2002. PMID: 11996943 Clinical Trial.
1,384 results